UNITED STATES OF AMERICA
Before the
SECURITIES AND EXCHANGE COMMISSION

April 15, 2020

In the Matter of

Signpath Pharma Inc.

File No. 500-1

ORDER OF SUSPENSION OF TRADING

It appears to the Securities and Exchange Commission that the public interest and the protection of investors require a suspension of trading in the securities of Signpath Pharma Inc. (“SGTH”) (CIK # 0001455694) due to questions and concerns regarding the accuracy and adequacy of publicly available information concerning SGTH, including a public claim made by SGTH on March 17, 2020, regarding SGTH’s development of a COVID-19 treatment, together with a lack of current financial information in the marketplace. SGTH is a Delaware corporation with its principal place of business in Sandy, Utah. The company’s common stock is quoted on OTC Link (previously Pink Sheets) operated by OTC Markets Group Inc. under the symbol SGTH. As of April 8, 2020, SGTH, had four market makers, and was eligible for the “piggyback” exception of Exchange Act Rule 15c2-11(f)(3).

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed company.
THEREFORE, IT IS ORDERED, pursuant to Section 12(k) of the Exchange Act, that trading in the securities of the above-listed company is suspended for the period from 9:30 a.m. EDT, on April 16, 2020 through 11:59 p.m. EDT, on April 29, 2020.

By the Commission.

Vanessa A. Countryman
Secretary